Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Mackenzie Financial Corp

Mackenzie Financial Corp boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Rating) by 1,153.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 56,930 shares of the biopharmaceutical company’s stock after acquiring an additional 52,389 shares during the quarter. Mackenzie Financial Corp owned about 0.06% of Intra-Cellular Therapies worth $3,250,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ITCI. US Bancorp DE lifted its position in Intra-Cellular Therapies by 93.8% during the 2nd quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 240 shares during the period. Assetmark Inc. raised its stake in shares of Intra-Cellular Therapies by 410.0% during the 2nd quarter. Assetmark Inc. now owns 510 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 410 shares during the last quarter. Prospera Financial Services Inc purchased a new position in shares of Intra-Cellular Therapies in the 1st quarter valued at about $71,000. Exchange Traded Concepts LLC increased its stake in shares of Intra-Cellular Therapies by 138.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 1,299 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 754 shares in the last quarter. Finally, Envestnet Asset Management Inc. purchased a new position in shares of Intra-Cellular Therapies in the 2nd quarter valued at about $207,000. Institutional investors and hedge funds own 85.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ITCI shares. Needham & Company LLC lifted their price target on Intra-Cellular Therapies from $65.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, August 10th. Canaccord Genuity Group lifted their price target on Intra-Cellular Therapies from $90.00 to $93.00 in a research note on Friday, November 4th. The Goldman Sachs Group cut Intra-Cellular Therapies from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $64.00 to $49.00 in a report on Monday, August 22nd. StockNews.com upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Finally, Mizuho reiterated a “buy” rating and issued a $72.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, October 3rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $67.50.

Insider Transactions at Intra-Cellular Therapies

In other news, CFO Lawrence J. Hineline sold 65,164 shares of the business’s stock in a transaction that occurred on Wednesday, September 21st. The stock was sold at an average price of $45.63, for a total transaction of $2,973,433.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.70% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $51.94 on Monday. The stock has a market cap of $4.92 billion, a P/E ratio of -15.64 and a beta of 1.15. The stock’s 50 day simple moving average is $47.92 and its 200-day simple moving average is $52.30. Intra-Cellular Therapies, Inc. has a 1-year low of $34.43 and a 1-year high of $66.00.

Intra-Cellular Therapies Profile

(Get Rating)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.

See Also

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Rating).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.